JP Morgan Chase
AXDX

JP Morgan Chase’s Accelerate Diagnostics AXDX Stock Holding History

JP Morgan Chase’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-190
Closed -$21K – 5621
2020
Q3 		$21K Sell
190
-12,720
-99% -$1.77M ﹤0.01% 5132
2020
Q2 		$1.96M Buy
12,910
+7,890
+157% +$778K ﹤0.01% 3114
2020
Q1 		$418K Sell
5,020
-3,810
-43% -$536K ﹤0.01% 3906
2019
Q4 		$1.49M Buy
8,830
+8,180
+1,258% +$1.35M ﹤0.01% 3599
2019
Q3 		$121K Buy
+650
New +$126K ﹤0.01% 4822
2017
Q2 		– Sell
-2,000
Closed -$484K – 4950
2017
Q1 		$484K Buy
+2,000
New +$457K ﹤0.01% 3723
2014
Q4 		– Sell
-5,000
Closed -$1.07M – 4221
2014
Q3 		$1.07M Buy
+5,000
New +$972K ﹤0.01% 3293

Other funds holding AXDX

BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BCWM
Bartlett & Co Wealth Management Cincinnati, Ohio $7.82B AUM 15.4% 1-Year Est. Return

JP Morgan Chase's AXDX Position: Q2 2025 in Review

JP Morgan Chase sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 32 shares — an estimated $23 sold.

JP Morgan Chase first reported a position in AXDX in Q4 2015 and held it in 36 quarters. The position peaked at $2.2M in Q3 2022. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.

  • JP Morgan Chase reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 32 Accelerate Diagnostics shares in Q2 2025, an estimated $23.
  • JP Morgan Chase first reported a position in Accelerate Diagnostics in Q4 2015 and held it in 36 quarters.
  • JP Morgan Chase's Accelerate Diagnostics position peaked at $2.2M in Q3 2022.
  • 3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.